GEN Exclusives

More »

GEN News Highlights

More »
Feb 6, 2007

Sciele to Work on Fenofibrate and Pravastatin Combination

  • Sciele Pharma entered into an agreement with Galephar Pharmaceutical Research to develop and market a combination of fenofibrate and pravastatin to treat mixed dyslipidemia. Mixed dyslipidemia is the presence of elevated levels of LDL cholesterol and triglycerides and low levels of HDL cholesterol in the blood.

    Sciele will be responsible for the Phase III studies and all regulatory filings with the FDA. It expects to use data from clinical trials that were conducted in Europe to supplement these U.S. filings. The company plans to begin enrolling patients in the Phase III evaluation during the first half of 2007.

    Sciele will pay Galephar an upfront fee, a milestone payment after approval, and royalties on product sales. The company will have exclusive rights to bring this combination therapy to market in the U.S., Mexico, and Canada.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Climate Change and Disease

Are the incursions of dengue fever and West Nile virus into North America just the tip of the iceberg of insect-borne diseases that are migrating due to a warming planet?